LUND, SWEDEN / ACCESSWIRE / May 20, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today that both of the clinical sites in the phase I/IIa study Tumorad-01 are actively recruiting patients. So far two patients have been enrolled and successfully dosed. A third patient is enrolled and awaits treatment, with a fourth patient also identified. The study continues according to plan, with focus on recruiting patients with different tumor types.
LUND, SE / ACCESSWIRE / May 16, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)
LUND, SWEDEN / ACCESSWIRE / May 6, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) nnThis English version of the notice to the annual general meeting is for convenience only. The Swedish version prevails in the event of any inconsistency.
LUND, SWEDEN / ACCESSWIRE / May 2, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Positive start to an important year nnJANUARY - MARCH IN BRIEF nnNet sales for the quarter amounted to KSEK 350 (KSEK 88) nThe loss for the quarter amounted to KSEK -7.763 (KSEK -15.573) nOperating expenses for the quarter amounted to KSEK -9.497 (KSEK -17.168) nEarnings per share, before and after dilution, for the quarter amounted to SEK -0.03 (SEK -0.17) nCash and cash equivalents at the end of the quarter amounted to KSEK 32,250 (KSEK 45,106)
LUND, SWEDEN / ACCESSWIRE / April 24, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today data from a non-clinical study exploring 177Lu-SN201 in a model for triple-negative breast cancer. In the model, 177Lu-SN201 demonstrates superior anti-tumor effect compared to standard cancer drugs with a low and acceptable level of radiotoxicity observed.
LUND, SWEDEN / ACCESSWIRE / April 16, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) today announced the appointment of Birgitta Rembratt Svensson as Head of CMC & Supply. Birgitta, an experienced CMC project manager with several leading positions at development and commercial stage pharmaceutical companies, will join Spago Nanomedical on June 1 and serve as a member of the management team.
LUND, SWEDEN / ACCESSWIRE / February 7, 2024 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F) First cancer patient dosed with Tumorad®
LUND, SWEDEN / ACCESSWIRE / January 18, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today that the company will participate at Redeye's Fight Cancer event on January 24, 2024. At the event, Spago Nanomedical's CEO Mats Hansen will give an update on the company's radiopharma program Tumorad® and participate in a panel discussion on precision medicine.